辉瑞新冠疫苗测试据报暂有32人确诊 疫苗有效性未明
《路透》报道,美国药厂辉瑞希望与德国BioNTech合作研发的新冠疫苗,於临床测试初期能明显展示其有效性,以争取美国当局快速通过审批。辉瑞早前表示於10月底知悉疫苗能否安全有效,并会在证明有效後尽快寻求监管当局批准应用。
报道引述辉瑞向监管当局披露的文件表示,逾2.9万人参与测试,当中部分人获注射测试疫苗,其余则接受注射安慰剂,至今有32人感染新冠。报道引述文件指,该32人当中,不能多於6人曾接受测试疫苗注射,否则不能达到76.9%有效率,有关疫苗其後要面临更严格的有效率达标要求。
报道亦指,另一间研发新冠疫苗的Moderna药厂,已向美国当局提出在七成有效率下,寻求批准疫苗紧急使用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.